Format

Send to

Choose Destination
Neoplasia. 2017 Aug;19(8):637-648. doi: 10.1016/j.neo.2017.05.003. Epub 2017 Jul 11.

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.

Author information

1
Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy. Electronic address: mara.bonelli@unipr.it.
2
Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy. Electronic address: graziana.digiacomo@unipr.it.
3
Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy. Electronic address: claudia.fumarola@unipr.it.
4
Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy. Electronic address: roberta.alfieri@unipr.it.
5
Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy. Electronic address: federico.quaini@unipr.it.
6
Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy. Electronic address: angela_falco@hotmail.com.
7
Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy. Electronic address: denise.madeddu@unipr.it.
8
Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy. Electronic address: silvia.lamonica@unipr.it.
9
Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy. Electronic address: daniele.cretella@nemo.unipr.it.
10
Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy. Electronic address: andrea.ravelli@studenti.unipr.it.
11
Biosciences Laboratory, IRST-IRCCS, Meldola, Italy. Electronic address: paola.ulivi@irst.emr.it.
12
Biosciences Laboratory, IRST-IRCCS, Meldola, Italy. Electronic address: michela.tebaldi@irst.emr.it.
13
Biosciences Laboratory, IRST-IRCCS, Meldola, Italy. Electronic address: daniele.calistri@irst.emr.it.
14
Department of Medical Oncology, IRST-IRCCS, Meldola, Italy. Electronic address: angelo.delmonte@irst.emr.it.
15
Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy. Electronic address: luca.ampollini@unipr.it.
16
Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy. Electronic address: paolo.carbognani@unipr.it.
17
Division of Medical Oncology, University Hospital of Parma, Parma, Italy. Electronic address: mtiseo@ao.pr.it.
18
Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy. Electronic address: andrea.cavazzoni@unipr.it.
19
Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy. Electronic address: piergiorgio.petronini@unipr.it.

Abstract

Malignant pleural mesothelioma (MPM) is a progressive malignancy associated to the exposure of asbestos fibers. The most frequently inactivated tumor suppressor gene in MPM is CDKN2A/ARF, encoding for the cell cycle inhibitors p16INK4a and p14ARF, deleted in about 70% of MPM cases. Considering the high frequency of alterations of this gene, we tested in MPM cells the efficacy of palbociclib (PD-0332991), a highly selective inhibitor of cyclin-dependent kinase (CDK) 4/6. The analyses were performed on a panel of MPM cell lines and on two primary culture cells from pleural effusion of patients with MPM. All the MPM cell lines, as well as the primary cultures, were sensitive to palbociclib with a significant blockade in G0/G1 phase of the cell cycle and with the acquisition of a senescent phenotype. Palbociclib reduced the phosphorylation levels of CDK6 and Rb, the expression of myc with a concomitant increased phosphorylation of AKT. Based on these results, we tested the efficacy of the combination of palbociclib with the PI3K inhibitors NVP-BEZ235 or NVP-BYL719. After palbociclib treatment, the sequential association with PI3K inhibitors synergistically hampered cell proliferation and strongly increased the percentage of senescent cells. In addition, AKT activation was repressed while p53 and p21 were up-regulated. Interestingly, two cycles of sequential drug administration produced irreversible growth arrest and senescent phenotype that were maintained even after drug withdrawal. These findings suggest that the sequential association of palbociclib with PI3K inhibitors may represent a valuable therapeutic option for the treatment of MPM.

PMID:
28704762
PMCID:
PMC5508477
DOI:
10.1016/j.neo.2017.05.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center